Clark Kent, Hannah Montana, Dexter Morgan, David Bowie and your friendly neighborhood rheumatologist: What do all of these people have in common? Chances are, they live secret lives we rarely get to peer into. Unlike Superman, Miley Stewart, Dexter Morgan and Ziggy Stardust, rheumatologists are very much real, flesh-and-blood characters. Rheumatologists also have secret lives…
CPPD is notoriously difficult to diagnose due to its diverse presentations & uncertain etiology. Recent advances have helped rheumatologists better understand its risk factors, classify, diagnose & treat the condition.
In part 2 of Dr. Sam Shapiro’s journey, learn how she connected with the rheumatology community to change her career and found a better way to embrace her passions for clinical rheumatology, education and helping patients.
This spring, PANLAR designated Mary K. Crow, MD, a Master of Rheumatology. She was honored for her career in research and work extending research opportunities to investigators in Latin America.
The EULAR/ACR/APLAR Research Exchange Program is an opportunity to learn and exchange ideas within the rheumatology community internationally. Here the program’s most recent participants share their experiences & excitement.
In comments to the National Association of Insurance Commissioners, the ACR outlined several recommendations for a proposed state model law addressing the use of artificial intelligence in the insurance industry.
Last week, the Centers for Medicare & Medicaid Services (CMS) announced that it is implementing a new prior authorization model called the Wasteful and Inappropriate Services Reduction (WISeR) Model. This six-year model, starting on Jan. 1, 2026, aims to reduce fraud, waste and abuse in traditional Medicare by using technology-enabled processes for prior authorization and…
As of the close of the second quarter of CY2025, RheumPAC has raised $51,865 from 141 ACR members.
On July 1, Aetna launched its new Combined Benefit Management Drug List, effectively moving romosozumab-aqqg (Evenity) and infliximab (Remicade) to pharmacy-only coverage for most fully insured commercial plans. The ACR has contacted Aetna leaders to raise concerns about patient access to these therapies.
Dr. Samantha Shapiro recounts her enthusiastic and ambitious early career in rheumatology—a path that culminated in burnout and a brave choice with new opportunities.